1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. E-therapeutics plc
  6. News
  7. Summary
    ETX   GB00B2823H99

E-THERAPEUTICS PLC

(ETX)
  Report
Delayed London Stock Exchange  -  05/17 11:35:09 am EDT
22.80 GBX   -1.94%
05/04Earnings Flash (ETX.L) E-THERAPEUTICS Posts FY22 Revenue GBP477,000
MT
05/04Earnings Flash (ETX.L) E-THERAPEUTICS Posts FY22 Loss GBX-1.65
MT
05/04E-therapeutics plc Announces Change of Registered Office
CI
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

e therapeutics : Interim Results, July 2021 and RNAi Platform Development Presentation

10/26/2021 | 02:26am EDT

Integrating computational power and biology to discover life-transforming medicines

Interim results for six months ended 31 July 2021

Successful RNAi Platform

Development

October 2021

1

Legal Disclaimer

Forward looking statement

This document is being provided for the sole purpose of providing the recipients with background information about the business of e-therapeutics plc (the Company).

The information, statements and opinions contained in this document do not constitute a public offer under any applicable legislation or an offer to sell or solicitation of any offer to buy any securities or financial instruments or any advice or recommendation with respect to such securities or other financial instruments.

This document contains forward-looking statements including (without limitation) statements containing the words "believes", "expects", "estimates", "intends", "may", "plan", "will" and similar expressions (including the negative of those expressions). Forward-looking statements involve unknown risks, uncertainties and other factors which may cause the actual results, financial condition, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by those

forward-looking statements. Given these uncertainties, you are cautioned not to place any undue reliance on those forward- looking statements. The forward-looking statements contained in this document are made on the date of this document. The Company and its directors are not under any obligation to update those forward-looking statements in this document to reflect actual future events or developments.

This document (including the information in this disclaimer) does not constitute an offer, invitation or recommendation to subscribe for or purchase any security. Neither the document, this disclaimer nor anything contained in them forms the basis of any contract or commitment. No representation or warranty, express or implied, is or will be made in relation to the accuracy or completeness of the information in this document and all and such responsibility and liability is expressly disclaimed.

This document shall not exclude any liability for, or remedy in respect of, fraudulent misrepresentation.

2

Company Overview

Integrating computational power and biology to discover life-transforming medicines

Ability to model human biology and interrogate complexity for better and faster drug discovery

  • Experimentally validated computational platform centered around network biology
  • Increased translatability and improved probability of success

• Third party validation

Top5 Pharma

Competitive proprietary RNAi platform developed. Convergence with computational platform to rapidly identify and prosecute novel targets to unlock further value

Experienced leadership and growing multi-disciplinaryteam. Currently 34 FTE

Scope for future partnerships, across computational and RNAi platforms

Well-funded following recent £22.5m capital raise

3

Highlights (incl. post period)

Significantly strengthened cash position to facilitate a number of initiatives, expanding the Company's platform capabilities and acceleration of the development of in-house RNAi pipeline

RNAi platform development

  • Successful proprietary GalNAc-siRNAplatform developed and characterised. Equivalent performance to leading platforms demonstrated
  • 11 patent applications filed to protect innovative GalNAc-siRNA construct designs

Computational platform - zooming into hepatocytes

  • Hepatocyte Knowledge Graph created and ambitious experimental omics data strategy underway
  • Expanded target identification focus and creation of tailored computational applications in hepatocytes and RNAi
  • Increased automation and cloud computing

Collaborations - further validation of our computational platform

  • Galapagos collaboration: Hit compounds successfully identified and 3 milestone payments received during the period. Collaboration active and hits being further investigated. Scope for further milestones through pre-clinical, clinical and commercial

Corporate

  • Successful £22.5m gross fund raise from new and existing shareholders
  • Commenced trading on OTCQX Best Market in the U.S. - important step to broaden shareholder base
  • Board and leadership changes and significant increase in scientific staff

4

Financial Summary: Six months ended 31 July 2021

Six months ended

Six months ended

31 July 2021

31 July 2020

Revenue

£0.5m

£0.04m

Operating loss

£3.5m

£2.7m

Cash and cash equivalents

£31.6m

£15.1m*

R&D

£2.5m

£1.2m

Financial Highlights

  • Strengthened financial position following successful fund raise of £22.5m gross
  • Continued to carefully manage the underlying cash burn
  1. focusing on generating income and achieving external commercial validation with our partners and;
  1. investing in a new RNAi platform

Financial Outlook

  • Underlying cash burn in H2 expected to be higher than H1
  1. further progress R&D activities

o build administrative infrastructure to support scaling of business

* £13.0m as of 31 January 2021 5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

e-Therapeutics plc published this content on 26 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 October 2021 06:25:06 UTC.


ę Publicnow 2021
All news about E-THERAPEUTICS PLC
05/04Earnings Flash (ETX.L) E-THERAPEUTICS Posts FY22 Revenue GBP477,000
MT
05/04Earnings Flash (ETX.L) E-THERAPEUTICS Posts FY22 Loss GBX-1.65
MT
05/04E-therapeutics plc Announces Change of Registered Office
CI
05/04E-therapeutics plc Reports Earnings Results for the Full Year Ended January 31, 2022
CI
04/12E-therapeutics Achieves Key Milestones Under Collaboration with Galapagos
MT
04/05E-therapeutics Jumps 8% on Collaboration to Develop New Immuno-Oncology Therapies
MT
2021E-Therapeutics CFO to Step Down; Interim Finance Chief Named
MT
2021E-Therapeutics plc Announces Executive Changes
CI
2021Director Dealing – 26th October 2021
PU
2021E THERAPEUTICS : Interim Results, July 2021 and RNAi Platform Development Presentation
PU
More news
Financials
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 117 M 146 M 146 M
EV / Sales -1
EV / Sales 0
Nbr of Employees 35
Free-Float 36,0%
Chart E-THERAPEUTICS PLC
Duration : Period :
e-therapeutics plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends E-THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Managers and Directors
Ahmad Ali Mortazavi Chief Executive Officer & Director
Michael Anthony Bretherton Chief Financial Officer & Director
Trevor Mervyn Jones Independent Non-Executive Chairman
Alan Whitmore Chief Scientific Officer
Jonny Wray Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
E-THERAPEUTICS PLC-48.53%147
MODERNA, INC.-43.98%54 199
LONZA GROUP AG-28.13%40 453
IQVIA HOLDINGS INC.-26.74%39 077
SEAGEN INC.-5.21%26 238
ICON PUBLIC LIMITED COMPANY-32.47%17 114